Alterity Therapeutics Raises A$20.0 million in Strategic Placement
Alterity Therapeutics (NASDAQ: ATHE) has secured binding commitments for a A$20.0 million capital raise through a placement of fully paid ordinary shares to international and Australian professional investors. The placement was conducted at A$0.012 per share, representing a 7.7% discount to the last ASX closing price.
The funding follows positive Phase 2 clinical trial results for ATH434 in Multiple System Atrophy (MSA), which demonstrated clinically meaningful benefits and a favorable safety profile. The proceeds will support non-clinical studies, CMC activities, clinical and regulatory activities for ATH434's development in MSA, and general working capital. The company plans to engage with the FDA to discuss the path forward for ATH434's development.
Alterity Therapeutics (NASDAQ: ATHE) ha ottenuto impegni vincolanti per un aumento di capitale di A$20,0 milioni mediante un collocamento di azioni ordinarie totalmente liberate a investitori professionali internazionali e australiani. Il collocamento 猫 stato effettuato a A$0,012 per azione, pari a uno sconto del 7,7% rispetto all'ultimo prezzo di chiusura ASX.
Il finanziamento segue i risultati positivi dello studio clinico di Fase 2 su ATH434 nella Atrofia Multisistemica (MSA), che hanno evidenziato benefici clinicamente significativi e un profilo di sicurezza favorevole. I proventi sosterranno studi non clinici, attivit脿 CMC, attivit脿 cliniche e regolatorie per lo sviluppo di ATH434 nella MSA e il capitale circolante generale. L'azienda intende confrontarsi con la FDA per definire il percorso di sviluppo futuro di ATH434.
Alterity Therapeutics (NASDAQ: ATHE) ha asegurado compromisos vinculantes para una captaci贸n de capital de A$20,0 millones mediante una colocaci贸n de acciones ordinarias totalmente desembolsadas a inversores profesionales internacionales y australianos. La colocaci贸n se realiz贸 a A$0,012 por acci贸n, lo que representa un descuento del 7,7% respecto al 煤ltimo cierre en la ASX.
La financiaci贸n sigue a los resultados positivos del ensayo cl铆nico de Fase 2 de ATH434 en Atrofia Multisist茅mica (MSA), que mostraron beneficios cl铆nicamente relevantes y un perfil de seguridad favorable. Los fondos se destinar谩n a estudios no cl铆nicos, actividades CMC, actividades cl铆nicas y regulatorias para el desarrollo de ATH434 en MSA y a capital de trabajo general. La compa帽铆a planea reunirse con la FDA para definir el siguiente paso en el desarrollo de ATH434.
Alterity Therapeutics (NASDAQ: ATHE)電� 甑牅 氚� 順胳＜ 鞝勲 韴瀽鞛愲摛鞚� 雽�靸侅溂搿� 氤错喌欤� 鞝勳暋 雮╈瀰 氚╈嫕鞚� 氚办爼鞚� 韱淀暣 A$20.0氚彪 攴滊鞚� 鞛愱笀 臁半嫭鞐� 雽�頃� 甑啀霠� 鞛堧姅 鞎届啀鞚� 頇曤炒頄堨姷雼堧嫟. 鞚措矆 氚办爼鞚� 欤茧嫻 A$0.012鞐� 鞚措（鞏挫鞙茧┌, 鞚措姅 歆侅爠 ASX 膦呹皜 雽�牍� 7.7% 頃犾澑鞐� 頃措嫻頃╇媹雼�.
鞚措矆 鞛愱笀臁半嫭鞚� ATH434鞚� 雼り硠韱� 鞙勳稌歃�(MSA) 雽�靸� 2靸� 鞛勳儊鞁滍棙鞐愳劀 鞛勳儊鞝侅溂搿� 鞚橂 鞛堧姅 須臣鞕� 鞖绊樃鞝侅澑 鞎堨爠靹� 頂勲韺岇澕鞚� 頇曥澑頃� 旮嶌爼鞝� 瓴瓣臣鞐� 霐半ジ 瓴冹瀰雼堧嫟. 靾橃澋旮堨潃 牍勳瀯靸� 鞐瓣惮, CMC 頇滊彊, ATH434鞚� MSA 臧滊皽鞚� 鞙勴暅 鞛勳儊 氚� 攴滌牅 頇滊彊, 鞚茧皹 鞖挫爠鞛愲掣鞚� 歆�鞗愴晿電� 雿� 靷毄霅� 鞓堨爼鞛呺媹雼�. 須岇偓電� ATH434 臧滊皽鞚� 頄ロ泟 瓴诫毳� 雲检潣頃橁赴 鞙勴暣 FDA鞕� 順戩潣頃� 瓿勴殟鞛呺媹雼�.
Alterity Therapeutics (NASDAQ: ATHE) a obtenu des engagements contraignants pour une lev茅e de fonds de A$20,0 millions via un placement d'actions ordinaires lib茅r茅es aupr猫s d'investisseurs professionnels internationaux et australiens. Le placement a 茅t茅 r茅alis茅 脿 A$0,012 par action, soit une d茅cote de 7,7 % par rapport au dernier cours de cl么ture 脿 l'ASX.
Ce financement fait suite aux r茅sultats positifs de l'essai clinique de phase 2 d'ATH434 dans l'atrophie multisyst茅mique (MSA), qui ont montr茅 des b茅n茅fices cliniquement significatifs et un profil de s茅curit茅 favorable. Les produits serviront 脿 financer des 茅tudes non cliniques, des activit茅s CMC, des activit茅s cliniques et r茅glementaires pour le d茅veloppement d'ATH434 dans la MSA, ainsi que le fonds de roulement g茅n茅ral. La soci茅t茅 pr茅voit de s'entretenir avec la FDA pour discuter de la suite du d茅veloppement d'ATH434.
Alterity Therapeutics (NASDAQ: ATHE) hat verbindliche Zusagen f眉r eine Kapitalerh枚hung in H枚he von A$20,0 Millionen durch eine Platzierung von voll eingezahlten Stammaktien bei internationalen und australischen Profi-Investoren erhalten. Die Platzierung erfolgte zu A$0,012 pro Aktie, was einem Abschlag von 7,7% gegen眉ber dem letzten ASX-Schlusskurs entspricht.
Die Mittelzufuhr erfolgt nach positiven Ergebnissen der Phase-2-Studie mit ATH434 bei der Multisystematrophie (MSA), die klinisch relevante Vorteile und ein g眉nstiges Sicherheitsprofil zeigte. Die Erl枚se werden nichtklinische Studien, CMC-Aktivit盲ten, klinische und regulatorische Ma脽nahmen f眉r die Entwicklung von ATH434 bei MSA sowie das allgemeine Working Capital unterst眉tzen. Das Unternehmen plant, mit der FDA 眉ber den weiteren Entwicklungsweg von ATH434 zu sprechen.
- Successful raise of A$20.0 million with modest 7.7% discount and no options
- Positive Phase 2 clinical trial results showing clinically meaningful benefit for ATH434
- Strategic investment from high-quality international healthcare-focused fund
- Strengthened institutional register and balance sheet for pursuing partnerships
- 7.7% share price dilution for existing shareholders
Insights
Alterity secures A$20M funding following positive Phase 2 MSA trial results, strengthening its position for regulatory discussions and partnerships.
Alterity Therapeutics has secured
The financing was anchored by a high-quality international healthcare-focused fund, which speaks to the growing institutional confidence in Alterity's clinical program. Notably, this capital raise was executed without warrants or options, avoiding potential future dilution that often accompanies biotech fundraising at this stage.
The timing is strategically significant as it follows the company's announcement of "robust efficacy" demonstrated in their Phase 2 MSA trials. The funds will specifically support non-clinical studies, chemical manufacturing and controls (CMC) activities, and regulatory engagement - all critical components for advancing ATH434 toward potential approval.
Perhaps most importantly, management has indicated they will use this strengthened balance sheet position to pursue strategic partnerships, suggesting they're preparing for potential licensing deals or other collaborative arrangements that could further accelerate development. The planned FDA engagement to discuss the regulatory pathway forward represents a critical near-term catalyst that could significantly impact the company's timeline to potential commercialization.
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (鈥淎lterity鈥� or 鈥渢he Company鈥�), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced聽it has received binding commitments for a capital raising of A
"We are thankful for the continued interest from the investment community following the robust efficacy we demonstrated in our Phase 2 clinical trial in Multiple System Atrophy. We look forward to an exciting twelve months ahead as we actively pursue the path to approval,鈥� said, David Stamler, M.D., Chief Executive Officer of Alterity. 鈥淲e elected to execute this placement due to inbound interest from a high-quality international healthcare-focused fund that anchored the transaction. Based on the promising outlook for the company, we raised these funds at a modest discount with no options. The additional funding allows us to continue advancing our clinical and regulatory strategy for ATH434 with the US FDA and other agencies, while at the same time it strengthens our institutional register and balance sheet to best position the company for pursuing strategic partnerships.鈥�
MST Financial Services Pty Ltd (MST) acted as sole manager of the offering.
Placement details
The Placement was conducted at A
Use of Proceeds
The use of proceeds from this financing will provide Alterity a strong balance sheet to fund the necessary non-clinical studies, chemical manufacturing and controls (CMC) activities, clinical and regulatory activities for future development of ATH434 in MSA, and general working capital.
During 2025, Alterity has released positive topline results from its ATH434-201 and ATH434-202 Phase 2 clinical trials of ATH434. The data have demonstrated a clinically meaningful benefit and a favorable safety profile. Based on the strength of these Phase聽2 data, the company plans to engage with the FDA to discuss the path forward for future development of ATH434.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living聽with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson鈥檚 disease and related disorders. Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive data in its open label Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the 颁辞尘辫补苍测鈥檚 website at .
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Ana Luiza Harrop
+61 452 510 255
U.S.
Remy Bernarda
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled 鈥凌颈蝉办 贵补肠迟辞谤蝉鈥� in the 颁辞尘辫补苍测鈥檚 filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the 颁辞尘辫补苍测鈥檚 drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the 颁辞尘辫补苍测鈥檚 patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
FAQ
How much did Alterity Therapeutics (ATHE) raise in their September 2025 placement?
What was the pricing of ATHE's September 2025 share placement?
What will Alterity Therapeutics use the placement proceeds for?
What were the Phase 2 clinical trial results for Alterity's ATH434?
Who managed ATHE's September 2025 placement?
